A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy

BMC Infectious Diseases

W Conrad Liles⁷  Julie Overbaugh⁶  R Scott McClelland⁵  Benson BA Estambale¹  Walter Jaoko⁴  Kenneth A Tapia²  Nimerta Rajwans³  Susan M Graham⁴ 

[1] University of Nairobi Institute of Tropical and Infectious Diseases (UNITID), College of Health Sciences, University of Nairobi, Nairobi, Kenya;Department of Global Health, University of Washington, Seattle, WA 98195, USA;S.A. Rotman Laboratories, McLaughlin-Rotman Centre for Global Health, Toronto General Hospital-University Health Network, University of Toronto, Toronto, Ontario, M5G 2C4, Canada;Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya;Department of Epidemiology, University of Washington, Seattle, WA 98195, USA;Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA;Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Ontario, M5G 2C4, Canada

关键词: Endothelium;    Angiopoietin-2;    Angiopoietin-1;    E-selectin;    VCAM-1;    ICAM-1;    HAART;    HIV-1;   

Others  :  1147946
DOI  :  10.1186/1471-2334-13-263

 received in 2012-10-11, accepted in 2013-06-01,  发布年份 2013

【 摘 要 】

Background

HIV-1-related inflammation is associated with increased levels of biomarkers of vascular adhesion and endothelial activation, and may increase production of the inflammatory protein angiopoietin-2 (ANG-2), an adverse prognostic biomarker in severe systemic infection. We hypothesized that antiretroviral therapy (ART) initiation would decrease endothelial activation, reducing plasma levels of ANG-2.

Methods

Antiretroviral-naïve Kenyan women with advanced HIV infection were followed prospectively. Endothelial activation biomarkers including soluble intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), and E-selectin, and plasma ANG-2 and angiopoietin-1 (ANG-1) were tested in stored plasma samples from 0, 6, and 12 months after ART initiation. We used Wilcoxon matched-pairs signed rank tests to compare endothelial activation biomarkers across time-points, generalized estimating equations to analyze associations with change in log₁₀-transformed biomarkers after ART initiation, and Cox proportional-hazards regression to analyze associations with mortality.

Results

The 102 HIV-1-seropositive women studied had advanced infection (median CD4 count, 124 cells/μL). Soluble ICAM-1 and plasma ANG-2 levels decreased at both time-points after ART initiation, with concomitant increases in the beneficial protein ANG-1. Higher ANG-2 levels after ART initiation were associated with higher plasma HIV-1 RNA, oral contraceptive pill use, pregnancy, severe malnutrition, and tuberculosis. Baseline ANG-2 levels were higher among five women who died after ART initiation than among women who did not (median 2.85 ng/mL [inter-quartile range (IQR) 2.47–5.74 ng/mL] versus median 1.32 ng/mL [IQR 0.35–2.18 ng/mL], p = 0.01). Both soluble ICAM-1 and plasma ANG-2 levels predicted mortality after ART initiation.

Conclusions

Biomarkers of endothelial activation decreased after ART initiation in women with advanced HIV-1 infection. Changes in plasma ANG-2 were associated with HIV-1 RNA levels over 12 months of follow-up. Soluble ICAM-1 and plasma ANG-2 levels represent potential biomarkers for adverse outcomes in advanced HIV-1 infection.

【 授权许可】

   
2013 Graham et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Phillips AN, Neaton J, Lundgren JD: The role of HIV in serious diseases other than AIDS. AIDS 2008, 22:2409-2418.
• [2]Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD: Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010, 201:1788-1795.
• [3]Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD, INSIGHT SMART Study Group: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5:e203.
• [4]Baker J, Quick H, Hullsiek KH, Tracy R, Duprez D, Henry K, Neaton JD: Interleukin-6 and D-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection. HIV Med 2010, 11:608-609.
• [5]Baker J, Ayenew W, Quick H, Hullsiek KH, Tracy R, Henry K, Duprez D, Neaton JD: High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis 2010, 201:285-292.
• [6]Ford ES, Greenwald JH, Richterman AG, Rupert A, Dutcher L, Badralmaa Y, Natarajan V, Rehm C, Hadigan C, Sereti I: Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010, 24:1509-1517.
• [7]Dube MP, Sattler FR: Inflammation and complications of HIV disease. J Infect Dis 2010, 201:1783-1785.
• [8]Calza L, Pocaterra D, Pavoni M, Colangeli V, Manfredi R, Verucchi G, Chiodo F, Cantu M, Pariali M: Plasma levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. J Acquir Immune Defic Syndr 2009, 50:430-432.
• [9]de Larranaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA: Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res 2003, 110:93-98.
• [10]Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M, Swiss HIV Cohort Study: Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002, 185:456-462.
• [11]Papasavvas E, Azzoni L, Pistilli M, Hancock A, Reynolds G, Gallo C, Ondercin J, Kostman JR, Mounzer K, Shull J, Montaner LJ: Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption of antiretroviral therapy. AIDS 2008, 22:1153-1161.
• [12]Sipsas NV, Sfikakis PP, Touloumi G, Pantazis N, Choremi H, Kordossis T: Elevated serum levels of soluble immune activation markers are associated with increased risk for death in HAART-naive HIV-1-infected patients. AIDS Patient Care STDS 2003, 17:147-153.
• [13]Fiedler U, Augustin HG: Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006, 27:552-558.
• [14]Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA, Sukhatme VP: Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006, 3:e46.
• [15]Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N, Sobke A, Herrmann M, Preissner KT, Vajkoczy P, Augustin HG: Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006, 12:235-239.
• [16]Mankhambo LA, Banda DL, Jeffers G, White SA, Balmer P, Nkhoma S, Phiri H, Molyneux EM, Hart CA, Molyneux ME, Heyderman RS, Carrol ED, IPD Study Group: The role of angiogenic factors in predicting clinical outcome in severe bacterial infection in Malawian children. Crit Care 2010, 14:R91. BioMed Central Full Text
• [17]Graham SM, Masese L, Gitau R, Jalalian-Lechak Z, Richardson BA, Peshu N, Mandaliya K, Kiarie JN, Jaoko W, Ndinya-Achola J, Overbaugh J, McClelland RS: Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis 2010, 202:1538-1542.
• [18]Kenya Ministry of Health: Guidelines to antiretroviral drug therapy in Kenya. Nairobi: Kenya Ministry of Health; 2001.
• [19]Emery S, Bodrug S, Richardson BA, Giachetti C, Bott MA, Panteleeff D, Jagodzinski LL, Michael NL, Nduati R, Bwayo J, Kreiss JK, Overbaugh J: Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol 2000, 38:2688-2695.
• [20]Ricciuto DR, dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans N, Lafferty EI, Cook DJ, Fox-Robichaud A, Kahnamoui K, Kain KC, Liaw PC, Liles WC: Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 2011, 39:702-710.
• [21]Page AV, Kotb M, McGeer A, Low DE, Kain KC, Liles WC: Systemic dysregulation of angiopoietin-1/2 in streptococcal toxic shock syndrome. Clin Infect Dis 2011, 52:e157-e161.
• [22]Hartweg J, Gunter M, Perera R, Farmer A, Cull C, Schalkwijk C, Kok A, Twaalfhoven H, Holman R, Neil A: Stability of soluble adhesion molecules, selectins, and C-reactive protein at various temperatures: implications for epidemiological and large-scale clinical studies. Clin Chem 2007, 53:1858-1860.
• [23]Lukasz A, Hellpap J, Horn R, Kielstein JT, David S, Haller H, Kümpers P: Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays. Crit Care 2008, 12:R94. BioMed Central Full Text
• [24]United Nations Administrative Committee on Coordination Sub-Committee on Nutrition (ACC/SCN): Nutrition throughout the life cycle: 4th report on the world nutrition situation. Geneva: International Food Policy Research Institute; 2000.
• [25]Ren Z, Yao Q, Chen C: HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells. Lab Invest 2002, 82:245-255.
• [26]Kranidioti H, Orfanos SE, Vaki I, Kotanidou A, Raftogiannis M, Dimopoulou I, Kotsaki A, Savva A, Papapetropoulos A, Armaganidis A, Giamarellos-Bourboulis EJ: Angiopoietin-2 is increased in septic shock: evidence for the existence of a circulating factor stimulating its release from human monocytes. Immunol Lett 2009, 125:65-71.
• [27]Nixon DE, Landay AL: Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 2010, 5:498-503.
• [28]Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC, INSIGHT SMART Study Group: Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011, 203:780-790.
• [29]Dunk C, Shams M, Nijjar S, Rhaman M, Qiu Y, Bussolati B, Ahmed A: Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development. Am J Pathol 2000, 156:2185-2199.
• [30]Ye F, Florian M, Magder SA, Hussain SN: Regulation of angiopoietin and Tie-2 receptor expression in non-reproductive tissues by estrogen. Steroids 2002, 67:305-310.
• [31]Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU, Currie MJ: Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer 2011, 104:51-59.
• [32]Mehedint MG, Craciunescu CN, Zeisel SH: Maternal dietary choline deficiency alters angiogenesis in fetal mouse hippocampus. Proc Natl Acad Sci USA 2010, 107:12834-12839.
• [33]Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton J, INSIGHT SMART Study Group: Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011, 56:36-43.
• [34]Pettersen FO, Torheim EA, Dahm AE, Aaberge IS, Lind A, Holm M, Aandahl EM, Sandset PM, Taskén K, Kvale D: An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol 2011, 85:6557-6566.
• [35]Hileman CO, Carman TL, Storer N, Labbato DE, White CA, McComsey GA: Omega-3 fatty acids do not improve endothelial function in virologically-suppressed HIV-infected men: a randomized placebo-controlled trial. AIDS Res Hum Retroviruses 2012, 28:649-655.
• [36]Masia M, Bernal E, Padilla S, García N, Escribano JC, Martínez E, Gutiérrez F: A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk. J Antimicrob Chemother 2009, 64:589-598.
• [37]Pett SL, Kelleher AD, Emery S: Role of interleukin-2 in patients with HIV infection. Drugs 2010, 70:1115-1130.
• [38]Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, Piera K, Price RN, Duffull SB, Celermajer DS, Anstey NM: Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci USA 2008, 105:17097-17102.
• [39]Davis JS, Yeo TW, Piera KA, Woodberry T, Celermajer DS, Stephens DP, Anstey NM: Angiopoietin-2 is increased in sepsis and inversely associated with nitric oxide-dependent microvascular reactivity. Crit Care 2010, 14:R89. BioMed Central Full Text
• [40]Cao Y, Liu Q: Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv Cancer Res 2007, 97:203-224.